DK1198479T3 - Neovaskulamålrettet immunkonjugat - Google Patents

Neovaskulamålrettet immunkonjugat

Info

Publication number
DK1198479T3
DK1198479T3 DK00941443T DK00941443T DK1198479T3 DK 1198479 T3 DK1198479 T3 DK 1198479T3 DK 00941443 T DK00941443 T DK 00941443T DK 00941443 T DK00941443 T DK 00941443T DK 1198479 T3 DK1198479 T3 DK 1198479T3
Authority
DK
Denmark
Prior art keywords
immunoconjugates
alanine
factor vii
neovascular
effector domain
Prior art date
Application number
DK00941443T
Other languages
English (en)
Inventor
Alan Garen
Zhiwei Hu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK1198479T3 publication Critical patent/DK1198479T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00941443T 1999-07-01 2000-06-14 Neovaskulamålrettet immunkonjugat DK1198479T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14216199P 1999-07-01 1999-07-01
PCT/US2000/016481 WO2001002439A1 (en) 1999-07-01 2000-06-14 Neovascular-targeted immunoconjugates

Publications (1)

Publication Number Publication Date
DK1198479T3 true DK1198479T3 (da) 2008-10-13

Family

ID=22498780

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941443T DK1198479T3 (da) 1999-07-01 2000-06-14 Neovaskulamålrettet immunkonjugat

Country Status (11)

Country Link
EP (1) EP1198479B1 (da)
JP (2) JP2003504315A (da)
AT (1) ATE398633T1 (da)
AU (1) AU775621B2 (da)
CA (1) CA2377381C (da)
CY (1) CY1110394T1 (da)
DE (1) DE60039240D1 (da)
DK (1) DK1198479T3 (da)
ES (1) ES2307517T3 (da)
PT (1) PT1198479E (da)
WO (1) WO2001002439A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP1474451A2 (en) * 2002-02-13 2004-11-10 Micromet AG De-immunized (poly)peptide constructs
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
WO2003076461A2 (en) * 2002-03-12 2003-09-18 Novo Nordisk A/S Dimeric tf antagonist comprising two factor vii polypeptides
AU2003242506A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
JP2007511604A (ja) * 2003-11-18 2007-05-10 アイコニック セラピューティクス インコーポレイティッド キメラタンパク質の均質製剤
JP2009203161A (ja) * 2006-06-05 2009-09-10 Mebiopharm Co Ltd リウマチ治療薬
EA201291482A1 (ru) * 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
US20190015532A1 (en) 2016-01-15 2019-01-17 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
JP2019515904A (ja) * 2016-04-14 2019-06-13 アイコニック セラピューティクス，インコーポレイテッド 新血管新生に関連する障害を治療するための組成物および方法
WO2018091058A1 (en) 2016-11-17 2018-05-24 Rigshospitalet 177-lu labeled active site inhibited factor vii
AU2018235945A1 (en) * 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
CN111263640A (zh) * 2017-09-27 2020-06-09 俄亥俄州创新基金会 组织因子靶向car-nk和car-t细胞疗法
US20210069306A1 (en) * 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
CA2131528C (en) * 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
EP0771216B9 (en) * 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
US6156321A (en) * 1997-01-22 2000-12-05 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
ES2307517T3 (es) 2008-12-01
AU5614900A (en) 2001-01-22
EP1198479A1 (en) 2002-04-24
AU775621B2 (en) 2004-08-05
JP5745486B2 (ja) 2015-07-08
PT1198479E (pt) 2008-08-12
ATE398633T1 (de) 2008-07-15
CA2377381C (en) 2013-06-11
CA2377381A1 (en) 2001-01-11
JP2012255032A (ja) 2012-12-27
JP2003504315A (ja) 2003-02-04
CY1110394T1 (el) 2015-04-29
EP1198479A4 (en) 2004-10-20
DE60039240D1 (de) 2008-07-31
EP1198479B1 (en) 2008-06-18
WO2001002439A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
CY1110394T1 (el) Ανοσοσυζευγματα νεοαγγειακης στοχευσης
ES2224099T3 (es) Inmunotoxinas dirigidas contra antigenos de superficies relacionados con c-erbb-2 (her-2/neu).
AU665360B2 (en) Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
ATE246517T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
SA112330402B1 (ar) اتحادات جسم مضاد- عقار
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2013163229A1 (en) Dr5 ligand drug conjugates
ATE235257T1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Muñoz et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
KR20200135841A (ko) 고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
NZ335353A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
CA2366713A1 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
US5690935A (en) Biotherapy of cancer by targeting TP-3/P80
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
Rathore et al. Generation of active immunotoxins containing recombinant restrictocin
WO2004007557A3 (en) Tf antagonist
WO1990011779A1 (en) Heteroconjugates
JPH09500869A (ja) トキシンの治療的使用に対する副作用および非感受性を防ぐ方法
WO2022268050A1 (zh) 一种药物组合及其用途
IL95134A (en) METHOD AND PREPARATION FOR PREVENTING VIK VIRPOSIS IN ANIMAL CELLS BY USING HUMAN MONOCLONIDIAN ANTIGINAL ANTIBODY ANTIBODY AND ANTIVIRAL PROTEIN IN POCKWID PAIRS
NO168989B (no) Fremgangsmaate for aa oeke loeseligheten av f. eks. immunokonjugatpreparater
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
WO1994002174A1 (en) Immunocomplex
FR3085679B1 (fr) Composes analogues de la squalamine et leur utilisation medicale